Altimmune (ALT) revenue breakdown
By product, Research Grants and Contracts is the largest at 100% of fiscal 2018 revenue, growing -4% a year over 1 years.
Revenue by product
Fiscal years, as Altimmune reports them in its 10-K filings; fiscal 2018 total $10M.
| Products | 2017 | 2018 | Share |
|---|---|---|---|
| Research Grants and Contracts | $11M | $10M | 100% |
| License Revenue | $41,503 | $19,780 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ALT.
Open ALT in InvestinglyQuestions
Where does Altimmune make its money?
In fiscal 2018, by product: Research Grants and Contracts $10M, License Revenue $19,780.
From Altimmune's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.